Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
Table 1
Response measurement and hematologic toxicity/recovery time after 2 cycles of KRD-PACE.
Patient 1
Patient 2
Parameter
Staging studies at relapse before KRD-PACE
Staging studies after 2 cycles of KRD-PACE
Parameter
Staging studies at relapse before KRD-PACE
Staging studies after 2 cycles of KRD-PACE
ISS score (at diagnosis)
I
—
ISS score (at diagnosis)
III
—
Revised-ISS score (at diagnosis)
II
—
Revised-ISS Score (st diagnosis)
III
—
Cytogenetics/FISH (at diagnosis)
Monosomies 1, 8, 13, 14 and 17, which includes loss of the TP53 gene region
—
Cytogenetics/FISH (at diagnosis)
1q duplication. In addition, trisomy 6, 11, and 15, monosomy 13